WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial

Saved in:
Bibliographic Details
Published in:Journal of cystic fibrosis 2024-06, Vol.23, p.S11-S11
Main Authors: Castellani, C., Mondejar-Lopez, P., Quon, B.S., Alghisi, F., Fabrizzi, B., Ramsey, B., Tullis, E., McKone, E., Taylor-Cousar, J.L., Mall, M.A., Ahluwalia, N., Jennings, M., Tan, Y.V., Vinarsky, V., Waltz, D., Fajac, I.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1569-1993
1873-5010
DOI:10.1016/S1569-1993(24)00142-5